New method for characterising liposome formulated drugs
CF3 coupled with UV-Vis detection able to separate and quantify the amount of free drug in a liposome-drug product.
Postnova Analytics has published an application study that describes a new method for quantification of liposome encapsulated drug using Centrifugal Field-Flow Fractionation (CF3).
Nanoparticles, including liposomes, are increasingly used for delivery of drug molecules. During formulation of a liposome around a drug particle, a relatively large amount of free drug may remain unencapsulated and therefore not available for drug delivery via the liposomal carrier. For formulation groups adopting this drug delivery methodology it is important to quantify the amount of free versus encapsulated drug in a product to accurately determine the delivered dose of drug to a patient.
In this study, CF3 coupled with UV-Vis detection was shown to be able to separate and quantify the amount of free drug in a liposome-drug product. The separation data was verified using optical microscopy. The authors conclude that CF3 shows great promise for separation and quantification of drug particles, as the field of nanomedicine and liposomal drug delivery grows.
The Postnova CF2000 Series system is based on the CF3 principle using a centrifugal field as the driving force for the separation. Particles effected by this field are separated by dynamic diffusion based upon both their size and density. This unique feature allows researchers to separate different particle materials having the same particle size. The separation can be further optimized by the use of different eluents and rotation speed programs. The CF2000 has shown great utility for the separation of complex nanoparticle samples in application areas including pharmaceuticals, environmental research, food, cosmetics and agrochemicals.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance